Shots:
- IQVIA is expanding its collaboration with Kexing Biopharm to advance a global multi-product biosimilar development and commercialization program
- As part of the collaboration, IQVIA will provide end-to-end development, regulatory, analytics, and commercialization support to accelerate Kexing’s global biosimilar expansion while maintaining high quality and scientific standards
- The collaboration also integrates IQVIA’s AI-enabled clinical trial capabilities to streamline protocol design, site selection, and study execution, accelerating development and improving trial efficiency
Ref: Bussinesswire| Image: IQVIA and Kexing Biopharm| Press Release
Related News: Henlius and Organon Receive the EC Approval for Poherdy (Biosimilar, Perjeta)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
